Announcements Trials
Browse Landscape

Phase

Phase 2 43Phase 3 13Phase 4 10Phase 1 3Phase NA 2Phase 1/2 2Phase EARLY_PHASE1 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Head & Neck 1CNS 1

Conditions

Nasopharyngeal Carcinoma 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

pembrolizumab 410Cyclophosphamide 394Carboplatin 306Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 210Bevacizumab 209fludarabine 192Docetaxel 187Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 120Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × icotinib × Clear all
NCT01534585 2018-04-17

Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma

Taizhou Hospital

Phase 1/2 Completed
48 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT01516983 2014-02-17

Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation

Betta Pharmaceuticals Co., Ltd.

Phase 1/2 Completed
15 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡